

DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS



15 JUNE 2017

MEMORANDUM FOR SGVT

ATTN: CAPT KELSEY A CACIC

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- Your paper, entitled <u>Concentrations of Serum Inflammatory Markers after Hypobaric Exposure in Aircrew Trainees</u> presented at/published to <u>MHSRS, Kissimee, FL, 27-30 Aug 2017</u> in accordance with MDWI 41-108, has been approved and assigned local file #17264.
- 2. Pertinent biographic information (name of author(s) title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist's Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.
- 4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

Linda Steel-Goodwin

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

- 1. The author must complete page two of this form:
 - a. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D;
 Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed
 Medical Research Program (CDMRP); Grants; etc.]
 - b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- 5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
 - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- 7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.
- 8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- 11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING OF PROFESSION	PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS							
1. TO: CLINICAL RESEARCH 2. FROM: (Auth					PROTOCOL NUMBER:			
Kelsey A. Caci			∑ YES □ N	10 F	WH20140087H			
5. PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.)								
MRI Following Single Exposure to Hypobaria and/or Hypoxia Protocol								
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:								
Concentrations of Serum Inflammatory Markers after Hypobaric Exposure in Aircrew Trainees								
7. FUNDING RECEIVED FOR THIS STUDY? ▼ YES NO FUNDING SOURCE: AFMS RDT&E								
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: YES NO								
9. IS THIS MATERIAL CLASSIFIED? YES X NO								
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? YES NO NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.								
11. MATERIAL IS FOR: ☑ DOMESTIC RELEASE ☐ FOREIGN RELEASE								
CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED. 11a. PUBLICATION/JOURNAL (List intended publication/journal.)								
11b. PUBLISHED ABSTRACT (List intended journal.)								
11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meting.)								
11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)								
12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED?								
☐ YES ☑ NO ASSIGNED FILE # DATE								
13. EXPECTED DATE WHEN YOU WILL NEED THE CRD TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC NOTE: All publications/presentations are required to be placed in the Defense Technical Information Center (DTIC).								
DATE								
01Jul2017								
14. 00 mest i i i i i i i i i i i i i i i i i i i			15. DUTY 220-0847	PHONE/PAGER NUMBER				
16. AUTHORSHIP AND CO-AUTHOR(S) List in	n the order they will appe	ar in the manuscript.						
LAST NAME, FIRST NAME AND M.I.	GRADE/RANK	SQUADRON/GROUP/0	OFFICE SYMBOL	INSTI	TUTION (If not 59 MDW)			
a. Primary/Corresponding Author	02	OSO COROLOCUE		SAMMC				
Cacic, Kelsey A b. Sladky, John H	03	959 CSPS/SGVT 959 MDOS/SGOT		SAMMC				
THE STATE OF THE S	06	USAF School of Aerospace Medicine		Wright-Patterson				
c. Sherman, Paul d. McGuire, Steven	RETIRED	59 MDW & USAFSAM						
	RETIRED	22.112.11.22						
e.	HOED (JED DOD SEES OF	7 DIA TO VEG 17 NO						
17. IS A 502 ISG/JAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? YES NO I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR								
1 CERTIFY ANY HUMAN OR ANIMAL RESEAR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108 ACCURATE MANUSCRIPT FOR PUBLICATIO	. I HAVE READ THE FIN	IAL VERSION OF THE ATTA ION.	ACHED MATERIAL A	ND CERTI	FY THAT IT IS AIN			
18. AUTHOR'S PRINTED NAME, RANK, GRADE Kelsey A Cacic, 03			AUTHOR'S SIGNATURE DIC.KELSEY.A.1465222766		20. DATE 08Jun2017			
21. APPROVING AUTHORITY'S PRINTED NA JEFFREY C. McCLEAN, Lt Col, Neurold		22. APPROVING AUTHORITY'S SIGNATURE MCGLEANJEFFREY.C.II.1022417343		23. DATE 12Jun2017				

PROCESSING OF PROFESSIONAL MEDICAL	RESEAR	RCH/TECHNICAL PUBLICATIONS/PRESI	NTATIONS				
1st ENDORSEMENT (59 MDW/SGVU Use Only) TO: Clinical Research Division 24 DATE RECEIVED		25. ASSIGNED PROCESSING REQUEST FILE NU	MRED				
TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions. 24. DATE RECEIVED June 12, 2017		17264	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z				
26. DATE REVIEWED		27. DATE FORWARDED TO 502 ISG/JAC					
14 Jun 2017							
28. AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES: NO XYES If yes, give date. 14 Jun 2017 N/A							
29. COMMENTS APPROVED DISAPPROVED							
The author added the human research disclaimer statement to study. The poster presentation is approved.	the poster	presentation and provided the IRB approval let	ter for the research				
30. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER		31. REVIEWER SIGNATURE	32. DATE				
Rocky Calcote, PhD, Clinical Research Administrator		CALCOTE.ROCKY.D.1178245844 Displict region is GALCOTE ROCKY D.117045844 Displict region is GALCOTE ROCKY D.1170458444 Displict region is GALCOTE ROCKY D.11704584444 Displict region is GALCOTE ROCKY D.11704584444 Displict region is GALCOTE ROCKY D.11704584444444 Displict region is GALCOTE ROCKY D.117045844444444444444444444444444444444444	June 15, 2017				
2nd ENDORSEMENT (502 ISG/JAC Use Only)		34. DATE FORWARDED TO 59 MDW/PA					
33. DATE RECEIVED		34. DATE FORWARDED TO 59 MDW/FA					
36. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER		37. REVIEWER SIGNATURE	38. DATE				
3rd ENDORSEMENT (59 MDW/PA Use Only)							
39. DATE RECEIVED		40. DATE FORWARDED TO 59 MDW/SGVU					
June 15, 2017		June 15, 2017					
41. COMMENTS APPROVED (In compliance with security and policy review directives.)							
42. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER	43. REVIEWER SIGNATURE	44. DATE					
Kevin linuma, SSgt/E-5, 59 MDW Public Affairs		IINUMA.KEVIN.MITSUGU.1296227 Open ale iş indaka KYDNATTAGU ÜDROZPAT. 61. ale ili di Generale ale ili della peri il mendiere della peri ili mendiere della peri ili mendiere della peri ili della per	June 15, 2017				
4th ENDORSEMENT (59 MDW/SGVU Use Only)							
45. DATE RECEIVED	46. SENIC	OR AUTHOR NOTIFIED BY PHONE OF APPROVAL NO COULD NOT BE REACHED LE	OR DISAPPROVAL FT MESSAGE				
47. COMMENTS APPROVED DISAPPROVED 48. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER		49. REVIEWER SIGNATURE	50. DATE				
48. PRINTED NAME, RANKOGRADE, TITLE OF REVIEWER		IV. 16 TIGITAL VIOLET II VIIIA					





Concentrations of Serum Inflammatory Markers after Hypobaric Exposure in Aircrew Trainees



San Antonio Uniformed Services Health Education Consortium, San Antonio, TX; Department of Neurology, 59th Medical Wing, Joint Base San Antonio - Lackland, TX; 3n Antonio - Lackland, Kelsey A. Cacic¹; John H. Sladky²; Paul Sherman³; Stephen A. McGuire^{2,3}

BACKGROUND

inflammatory serum markers. 1.2 The aim of this study is to various Recurrent non-hypoxic hypobaric exposure in Air Force U-2 understood but may be related to quantitative changes in assess whether protein and cytokine concentrations change non-hypoxic hypobaric exposure. We hypothesized that inflammatory markers, which elevate in decompression neurocognitive performance, would change in response to neurocognitive performance with parallel diffuse axonal pathophysiology of this brain injury is not well injury demonstrated on magnetic resonance imaging (MRI) and with traumatic brain injury (TBI), acquired associated conditions associated hypobaric exposure. neurological sickness, after

SERUM MARKERS

a-IFN: Biomarker of neuro-inflammation

TNF: Higher levels after TBI have been correlated with more severe injuries3

IL-6: Cytokine, seen elevated after severe TBI subarachnoid hemorrhage3:

SB-100: S-100 calcium binding protein B, elevate with hypoxic hypobaric injury,6 increase with greater injury severity and decreased survival?

Subjects: 75 aircrew trainees (AFC) and 50 controls (NOR) matched for age, health, and physical activity levels

Exposure: Aircrew chamber training: 100% O2 @ 25,000 ft Data Collection: Serum was collected 30 min before, 30 min at 4.5 psi; approximately 30 min hypobaric, 2-5 min hypoxic

Analysis: Within-group two-tailed paired t-test between after, 24 h, 72 h in relation to exposure

time points


RESULTS

Concentrations of serum markers

changes in serum SB-100 concentrations without clinical symptoms, demonstrating possible secondary response to hypobaric exposure. Prior research has demonstrated SB-100 involvement with blood-brain barrier regulation, an etiology that is thought to be involved in hypobaric-induced pathophysiology,⁶ SB-100 has also received recent attention as a biomarker for TBI associated with cell division, apoptosis, and inflammation.⁷ Changes in SB-100 after hypobaric

his study provides evidence of inflammatory marker

CONCLUSION



exposure may help explain the pathophysiology for the pattern of damage seen on imaging. Limitations of this be conducted in a research lab. Further research is


study include clinical lab analysis; further analyses will needed to elucidate involvement of other inflammatory

cytokines and effects of repeated

hypobaric exposure.

FUTURE DIRECTIONS

ince intervals with alpha 0.05



SB-100

Phase 3 Recurrent Exposure (Swine) Consider additional biomarkers Phase 3 Single Exposure Human CSF and serum biomarkers U-2 pilot occupational MRI

BIBLIOGRAPHY

- mammatory cytokines after traumatic brain injury. Brain

in the exposure group from pre-hypobaric exposure to post-hypobaric exposure without significant change 24 h or 72 h after exposure. There were no statistically significant differences in α-IFN, TNF, or IL-6 concentrations compared to baseline

Within-group two-tailed paired t-test analysis demonstrated a decrease in SB-100

confidence intervals with alpha 0.05

ooks Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the U.S. Army, the U.S. Air Force, the Depar was obtained as required by 32 CR 219 and DDDI 3216.02 AF40-402. The views expressed are the Defense, or the U.S. Govern

at any time points.

Montatio M, et al. Multiples vaniyte seavy to characterise different dementas: bron es, na postubosta and other dementas, Neurobiol April, 2018; 18 56-67.

Le al. Systemic polinfarmatory response facilitates the development of cerebral reference